Minerva Neurosciences (NASDAQ:NERV) will post its quarterly earnings results before the market opens on Monday, August 3rd. Analysts expect Minerva Neurosciences to post earnings of ($0.30) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Monday, May 4th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.05. On average, analysts expect Minerva Neurosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ NERV opened at $3.49 on Friday. The firm’s 50 day simple moving average is $3.54 and its 200-day simple moving average is $6.84. Minerva Neurosciences has a 12 month low of $1.81 and a 12 month high of $15.22.
NERV has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Minerva Neurosciences in a research note on Thursday, July 2nd. William Blair reissued a “hold” rating on shares of Minerva Neurosciences in a research note on Thursday, July 2nd. BTIG Research dropped their price target on shares of Minerva Neurosciences from $23.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Jefferies Financial Group cut shares of Minerva Neurosciences from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Friday, May 29th. Finally, BidaskClub cut shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 30th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Minerva Neurosciences currently has a consensus rating of “Buy” and a consensus target price of $11.57.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Recommended Story: How is the LIBOR rate calculated?
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.